Noninvasive prenatal diagnostic methods
Prenatal genetic testing allows early detection of genetic disease in a fetus. Described herein are methods of detecting the presence or absence of a genetic variant in a region of interest in the genome of a fetus in a pregnant woman. The methods are noninvasive, and can use cell-free DNA (cfDNA) present in the plasma of the pregnant woman. A DNA library is constructed from the cfDNA, and DNA molecules comprising the region of interest or portions thereof are enriched and analyzed, for example by sequencing. The methods described herein can also rely on constructing a maternal haplotype to provide even higher resolution fetal genetic variant determination.
1. A method of detecting the presence or absence of a genetic variant in a region of interest in the genome of a fetus in a pregnant woman, comprising:
(a) extracting circulating cell-free DNA from a plasma sample of the pregnant woman;
(b) extracting maternal genomic DNA (gDNA) from a sample of the pregnant woman;
(c) preparing a first DNA library from said cell-free DNA, the first DNA library comprising a first population of DNA molecules comprising covalently linked molecular barcodes and that is enriched for a region of interest in said cell-free DNA, wherein the sequence of each molecular barcode differs from the sequence of every other molecular barcode;
(d) preparing a second DNA library from said gDNA, the second DNA library comprising a second population of DNA molecules comprising first and second covalently linked molecular barcodes and that is enriched for a region of interest in said gDNA, wherein the sequence of each molecular barcode differs from the sequence of every other molecular barcode;
(e) sequencing the region of interest in the first population of DNA molecules from said first DNA library to produce a plurality of cell-free DNA sequencing reads;
(f) sequencing a region of interest in the second population of DNA molecules from said second DNA library that corresponds to the region of interest in the cell-free DNA to produce a plurality of gDNA sequencing reads by performing long read-length sequencing technologies, wherein said long read-length sequencing technologies produces sequence reads greater than 500 bases, and constructing a maternal haplotype by phasing genetic variants present only in the gDNA sequencing reads; and
(g) detecting the presence or absence of a fetal genetic variant based on the cell-free DNA sequencing reads and the maternal haplotype,
wherein the fetal genetic variant is a single-nucleotide variant, a multi-nucleotide variant, an indel variant of 100 bp or less, or a copy number loss variant within a region of interest of 50,000 bp or fewer.
2. A method of detecting the presence or absence of a genetic variant in a region of interest in the genome of a fetus in a pregnant woman, comprising:
(a) extracting circulating cell-free DNA from a plasma sample of the pregnant woman;
(b) extracting maternal genomic DNA (gDNA) from a sample of the pregnant woman;
(c) preparing a first DNA library from said cell-free DNA, wherein the first DNA library comprises a first plurality of DNA molecules comprising molecular barcodes, wherein the sequence of each molecular barcode differs from the sequence of every other molecular barcode;
(d) preparing a second DNA library from said gDNA, wherein the second DNA library comprises a second plurality of DNA molecules comprising a first and a second set of molecular barcodes, wherein the sequence of each molecular barcode differs from the sequence of every other molecular barcode;
(e) sequencing the region of interest in the first plurality of DNA molecules to produce a plurality of cell-free DNA sequencing reads; and
(f) sequencing a region of interest in the second plurality of DNA molecules that corresponds to the region of interest in the first plurality of DNA molecules to produce a plurality of gDNA sequencing reads by performing long read-length sequencing technologies, wherein said long read-length sequencing technologies produces sequence reads greater than 500 bases, and constructing a maternal haplotype by phasing genetic variants present only in the gDNA sequencing reads; and
(g) detecting the presence or absence of a fetal genetic variant based on the cell-free DNA sequencing reads and the maternal haplotype,
wherein the fetal genetic variant is a single-nucleotide variant, a multi-nucleotide variant, an indel variant of 100 bp or less, or a copy number loss variant within a region of interest of 50,000 bp or fewer.
3. A method of detecting the presence or absence of a genetic variant in a region of interest in the genome of a fetus in a pregnant woman, comprising:
(a) obtaining a first population of DNA molecules from a first DNA library comprising a first plurality of DNA molecules comprising molecular barcodes, wherein the first DNA library is prepared from circulating cell-free DNA extracted from a plasma sample of the pregnant woman, wherein the first population of DNA molecules is enriched for a region of interest in said cell-free DNA, wherein the molecular barcodes are incorporated into the first plurality of DNA molecules prior to enrichment, and wherein the sequence of each molecular barcode differs from the sequence of every other molecular barcode;
(b) obtaining a second population of DNA molecules from a second DNA library comprising a second plurality of DNA molecules comprising a first and a second set of molecular barcodes, wherein the second DNA library is prepared from gDNA extracted from a sample of the pregnant woman, wherein the second population of DNA molecules is enriched for a region of interest in said gDNA, wherein the first and second sets of molecular barcodes are incorporated into the second plurality of DNA molecules prior to enrichment, and wherein the sequence of each molecular barcode differs from the sequence of every other molecular barcode;
(c) sequencing the region of interest in the first population of DNA molecules to produce a plurality of cell-free DNA sequencing reads; and
(d) sequencing a region of interest in the second population of DNA molecules that corresponds to the region of interest in the cell-free DNA to produce a plurality of maternal sequencing reads by performing long read-length sequencing technologies, wherein said long read-length sequencing technologies produces sequence reads greater than 500 bases, and constructing a maternal haplotype by phasing genetic variants present only in the maternal sequencing reads; and
(e) detecting the presence or absence of a fetal genetic variant based on the cell-free DNA sequencing reads and the maternal haplotype,
wherein the fetal genetic variant is a single-nucleotide variant, a multi-nucleotide variant, an indel variant of 100 bp or less, or a copy number loss variant within a region of interest of 50,000 bp or fewer.
4. A method of detecting the presence or absence of a genetic variant in a region of interest in the genome of a fetus in a pregnant woman, comprising:
(a) extracting circulating cell-free DNA from a plasma sample of the pregnant woman;
(b) extracting gDNA from a sample of the pregnant woman;
(c) preparing a first DNA library from said cell-free DNA, wherein the first DNA library comprises a first plurality of DNA molecules comprising covalently linked molecular barcodes, wherein a portion of the first plurality of DNA molecules is enriched for a region of interest in said cell-free DNA, wherein the molecular barcodes are incorporated into the first plurality of DNA molecules prior to enrichment, and wherein the sequence of each molecular barcode differs from the sequence of every other molecular barcode;
(d) preparing a second DNA library from said gDNA, wherein the second DNA library comprises a second plurality of DNA molecules comprising a first and a second set of covalently linked molecular barcodes, wherein a portion of the second plurality of DNA molecules is enriched for a region of interest that corresponds to the region of interest in said cell-free DNA, wherein the first and second sets of molecular barcodes are incorporated into the second plurality of DNA molecules prior to enrichment, and wherein the sequence of each molecular barcode differs from the sequence of every other molecular barcode;
(e) sequencing the region of interest in the portion of the first DNA library to produce a plurality of cell-free DNA sequencing reads; and
(f) sequencing the region of interest in the second DNA library that corresponds to the region of interest in the cell-free DNA to produce a plurality of maternal sequencing reads by performing long read-length sequencing technologies, wherein said long read-length sequencing technologies produces sequence reads greater than 500 bases, and constructing a maternal haplotype by phasing genetic variants present only in the maternal sequencing reads; and
(g) detecting the presence or absence of a fetal genetic variant based on the cell-free DNA sequencing reads and the maternal haplotype,
wherein the fetal genetic variant is a single-nucleotide variant, a multi-nucleotide variant, an indel variant of 100 bp or less, or a copy number loss variant within a region of interest of 50,000 bp or fewer.
5. The method of claim 1 , wherein preparation of the population of DNA molecules that is enriched for the region of interest carried out by PCR amplification.
6. The method of claim 1 , wherein preparation of the population of DNA molecules that is enriched for the region of interest is carried out by hybridization.
7. The method of claim 1 , wherein the method detects the presence of the fetal genetic variant.
8. The method of claim 1 , wherein the method detects the absence of the fetal genetic variant.
9. The method of claim 1 , wherein the region of interest in the genome of the pregnant woman that corresponds to the region of interest in the cell-free DNA is sequenced from DNA present in a maternal buffy coat.
10. The method of claim 1 , wherein detecting the presence or absence of the fetal genetic variant comprises:
computing a maternal allele frequency for the maternal sequencing reads;
computing a cell-free DNA allele frequency for the cell-free DNA sequencing reads; and
comparing the maternal allele frequency to the cell-free DNA allele frequency.
11. The method of claim 1 , wherein the fetal genetic variant is a single-nucleotide variant, and wherein detecting the presence or absence of the fetal genetic variant comprises using a molecular barcode to distinguish the single-nucleotide variant from random or systematic errors.
12. The method of claim 1 , wherein the fetal genetic variant is a DNA deletion variant.
13. The method of claim 1 , wherein the fetal genetic variant is a de novo variant.
14. The method of claim 1 , wherein the fetal genetic variant is an inherited variant.
15. The method of claim 14 , wherein the fetal genetic variant is maternally inherited.
16. The method of claim 14 , wherein the fetal genetic variant is paternally inherited.
17. The method of claim 1 , wherein the fetal genetic variant is an autosomal dominant variant.
18. The method of claim 1 , wherein the fetal genetic variant is an autosomal recessive variant.
19. The method of claim 18 , wherein the region of interest comprises a CFTR gene or a fragment thereof or a FGFR3 gene or a fragment thereof.
20. The method of claim 1 , wherein the fetal genetic variant is an X-linked recessive variant.
21. The method of claim 20 , wherein the region of interest is the Duchenne muscular dystrophy (DMD) gene or a fragment thereof.
22. The method of claim 1 , wherein said detecting comprises detection of a plurality of genetic variants.
23. The method of claim 22 , wherein the plurality of genetic variants are in the same region of interest.
24. The method of claim 23 , wherein the plurality of genetic variants are in different regions of interest.
25. The method of claim 1 , wherein the gestational age of the fetus is about 10 weeks or more.
26. The method of claim 2 , wherein the fetal genetic variant is an X-linked recessive genetic variant.
27. The method of claim 3 , wherein the fetal genetic variant is an X-linked recessive genetic variant.
28. The method of claim 4 , wherein the fetal genetic variant is an X-linked recessive genetic variant.
29. The method of claim 1 , wherein long read-length sequencing technologies comprises single molecule sequencing.
30. A method of preparing a sample for detection of the presence or absence of a genetic variant in a region of interest in the genome of a fetus in a pregnant woman, comprising:
(a) extracting circulating cell-free DNA from a plasma sample of the pregnant woman;
(b) extracting maternal genomic DNA (gDNA) from a sample of the pregnant woman;
(c) preparing a first DNA library from said cell-free DNA, wherein the first DNA library comprises a plurality of DNA molecules comprising molecular barcodes, wherein the sequence of each molecular barcode differs from the sequence of every other molecular barcode;
(d) preparing a second DNA library from said gDNA, wherein the second DNA library comprises a plurality of DNA molecules comprising a first set and a second set of molecular barcodes, wherein the sequence of each molecular barcode differs from the sequence of every other molecular barcode;
(e) sequencing the region of interest in the portion of the first DNA library to produce a plurality of cell-free DNA sequencing reads;
(f) sequencing a region of interest in the second population of DNA molecules from said second DNA library that corresponds to the region of interest in the cell-free DNA to produce a plurality of gDNA sequencing reads by performing long read-length sequencing technologies, wherein said long read-length sequencing technologies produces sequence reads greater than 500 bases;
(g) constructing a maternal haplotype by phasing genetic variants present only in the gDNA sequencing reads; and
(h) detecting the presence or absence of a fetal genetic variant based on the cell-free DNA sequencing reads and the maternal haplotype,
wherein the fetal genetic variant is a single-nucleotide variant, a multi-nucleotide variant, an indel variant of 100 bp or less, or a copy number loss variant within a region of interest of 50,000 bp or fewer.
31. The method of claim 30 , wherein the gDNA sequencing reads are phased using the first and second sets of molecular barcodes to reconstruct the phase relationship of variants in the gDNA in the region of interest.